CAMP4 Therapeutics (NASDAQ:CAMP) Director Richard Young Purchases 16,378 Shares of Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Richard Young purchased 16,378 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average cost of $1.65 per share, with a total value of $27,023.70. Following the completion of the purchase, the director directly owned 186,388 shares in the company, valued at $307,540.20. The trade was a 9.63% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

CAMP4 Therapeutics Stock Down 3.6%

CAMP opened at $4.01 on Thursday. The business has a fifty day moving average of $4.02 and a 200 day moving average of $4.31. The stock has a market cap of $208.24 million, a P/E ratio of -1.70 and a beta of 0.22. CAMP4 Therapeutics Corporation has a 52-week low of $1.32 and a 52-week high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%.The business had revenue of $1.29 million during the quarter. Equities analysts anticipate that CAMP4 Therapeutics Corporation will post -0.84 EPS for the current fiscal year.

Institutional Trading of CAMP4 Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CAMP. China Universal Asset Management Co. Ltd. purchased a new position in shares of CAMP4 Therapeutics in the 4th quarter valued at $61,000. Jefferies Financial Group Inc. purchased a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth $70,000. Bank of America Corp DE purchased a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth $86,000. OMERS ADMINISTRATION Corp bought a new stake in CAMP4 Therapeutics during the fourth quarter valued at about $115,000. Finally, Goldman Sachs Group Inc. bought a new stake in CAMP4 Therapeutics during the fourth quarter valued at about $115,000.

Trending Headlines about CAMP4 Therapeutics

Here are the key news stories impacting CAMP4 Therapeutics this week:

• Positive Sentiment: Insider buying signals management confidence. CEO Josh Mandel-Brehm, CFO Kelly Gold, Director Richard A. Young and insider Yuri Maricich collectively purchased 36,031 shares at $1.65 per share. The purchases increased their respective holdings, although the transactions were relatively small in dollar terms. Insider purchase filings
• Positive Sentiment: CAMP4 raised approximately $50.1 million in the second closing of its private placement. The proceeds are intended to fund CMP-002, the company’s lead antisense oligonucleotide candidate, and its early-stage pipeline. The financing included participation from institutional investors such as Janus Henderson, Balyasny Asset Management, Vivo Capital and 5AM Ventures. CAMP4 private placement announcement
• Positive Sentiment: CMP-002 moved closer to human testing. CAMP4 said it received Australian regulatory and ethics clearance to begin a Phase 1/2 trial for SYNGAP1-related disorder, a rare neurological disease with no approved disease-modifying therapies. Preclinical testing showed increased SYNGAP1 protein expression and improvements in disease-relevant animal models. CAMP4 financing and CMP-002 update
• Negative Sentiment: The financing is materially dilutive. CAMP4 issued more than 10.7 million common shares and approximately 21.9 million pre-funded warrants at roughly $1.53 per share-equivalent, potentially expanding the share count significantly. The discounted issuance may weigh on the stock even though it provides additional operating runway.
• Neutral Sentiment: Clinical execution remains the key catalyst and risk. The Phase 1/2 trial could provide important validation, but CMP-002 remains investigational and preclinical results do not guarantee safety or efficacy in humans.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Zacks Research cut shares of CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 15th. Weiss Ratings downgraded shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Rodman & Renshaw assumed coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price objective on the stock. Chardan Capital set a $6.50 price objective on CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. Finally, JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the company from $5.00 to $9.00 in a research note on Tuesday, June 16th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $8.36.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.